Evotec and Ferring targeting reproductive medicine in multi-year alliance

By Melissa Fassbender

- Last updated on GMT

(Image: getty/shironosov)
(Image: getty/shironosov)

Related tags Evotec Reproductive medicine Drug discovery Ferring Pharmaceuticals

Evotec AG and Ferring Pharmaceuticals are collaborating to discover and develop new small molecule therapies for the treatment of fertility and gynaecological conditions.

As per the multi-year strategic research alliance, Evotec​ will apply its drug discovery platform to design novel treatments and is eligible to receive undisclosed research funding and milestones.

The multi-target collaboration aims to deliver small molecule preclinical development and investigational new drug (IND) ready candidates, according to Evotec.

Per Falk, chief science officer of Ferring, said in a press release: "To achieve leadership in reproductive medicine and women's health, we are expanding beyond our historical expertise in peptides and tackling molecular targets that are best addressed using small molecule therapeutics.”

Evotec has announced several partnerships this year, including those with Celgene​, Almirall​, Novo Nordisk​, and Centogene​, among others.

Additionally, earlier this month, Evotec signed​ its fourth translational research agreement with Sanofi as part of a five-year alliance.

The companies in March announced​ that Sanofi would license more than ten R&D assets to Evotec as part of an open platform alliance designed to advance anti-infective drug discovery and development. The deal included an upfront payment of approximately $74m to cover research and development, administrative, and facility-based costs.

Related topics Preclinical Research Preclinical

Related news

Show more

Related product

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Follow us


View more